“Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s271. doi:10.25251/skin.7.supp.271.